1,25-DIHYDROXYVITAMIN D-3 POTENTIATES THE CYTOTOXIC EFFECT OF TNF ON HUMAN BREAST-CANCER CELLS

被引:52
作者
ROCKER, D
RAVID, A
LIBERMAN, UA
GARACHJEHOSHUA, O
KOREN, R
机构
[1] BEILINSON MED CTR,BASIL & GERALD FELENSTEIN MED RES CTR,IL-49100 PETAH TIQWA,ISRAEL
[2] TEL AVIV UNIV,SACKLER FAC MED,DEPT PHYSIOL & PHARMACOL,IL-69978 TEL AVIV,ISRAEL
[3] METAB DIS UNIT,PETAH TIQWA,ISRAEL
基金
以色列科学基金会;
关键词
VITAMIN-D; CALCITRIOL; TUMOR NECROSIS FACTOR; BREAST CANCER (HUMAN); ENDOTHELIUM;
D O I
10.1016/0303-7207(94)90198-8
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
We studied the effect of 1,25-dihydroxyvitamin D-3(1,25(OH)(2)D-3) on the cytotoxic action of TNF on MCF-7 human breast cancer cells and on adult bovine aortic endothelial cells. 1,25(OH)(2)D-3 increased the effect of TNF on MCF-7 cells but not on endothelial cells over a wide TNF concentration range. At a suboptimal concentration (1 ng/ml) the potentiation was twofold. The effect of 1,25(OH)(2)D-3 was specific, dose-dependent and apparent at a physiological concentration (0.1 nM) of the hormone. The potentiating effect of 1,25(OH)(2)D-3 on TNF action was abolished by cycloheximide indicating that their interaction requires protein synthesis. Addition of 1,25(OH)(2)D-3 13 h after TNF in a 28-h assay was sufficient to induce its full potentiating effect indicating that the hormone modulates a late event in the cytokine's action. These data suggest that some of the in vivo antitumor effects of 1,25(OH)(2)D-3 may be due to an increase in the anticancer activity of the immune system.
引用
收藏
页码:157 / 162
页数:6
相关论文
共 24 条
[1]   INDUCTION OF MANGANESE SUPEROXIDE-DISMUTASE BY TUMOR NECROSIS FACTOR IN HUMAN-BREAST CANCER MCF-7 CELL-LINE AND ITS TNF-RESISTANT VARIANT [J].
ASOH, K ;
WATANABE, Y ;
MIZOGUCHI, H ;
MAWATARI, M ;
ONO, M ;
KOHNO, K ;
KUWANO, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 162 (02) :794-801
[2]  
BELIZARIO JE, 1991, CANCER RES, V51, P2379
[3]   TOPICAL CALCIPOTRIOL TREATMENT IN ADVANCED BREAST-CANCER [J].
BOWER, M ;
COLSTON, KW ;
STEIN, RC ;
HEDLEY, A ;
GAZET, JC ;
FORD, HT ;
COOMBES, RC .
LANCET, 1991, 337 (8743) :701-702
[4]  
COLSTON KW, 1989, LANCET, V1, P188
[5]  
EISMAN JA, 1986, CANCER RES, V46, P5406
[6]  
EISMAN JA, 1989, P SOC EXP BIOL MED, V191, P221
[7]  
EISMAN JA, 1987, CANCER RES, V47, P21
[8]   TUMOR-NECROSIS-FACTOR - CHARACTERIZATION AT THE MOLECULAR, CELLULAR AND INVIVO LEVEL [J].
FIERS, W .
FEBS LETTERS, 1991, 285 (02) :199-212
[9]  
FINTER NB, 1967, J IMMUNOL, V98, P88
[10]  
FRAMPTON RJ, 1983, CANCER RES, V43, P4443